The study, published in the journal Cancer Causes & Control, was led by Neill Bates of the Department of Academic Affairs at the Brody School of Medicine at East Carolina University, together with urologist Michael Blute Jr., epidemiologist Dmitry Tumin, and family physician Parker Barnwell Jr. The research team set out to answer a deceptively simple question: after the US Preventive Services Task Force issued its landmark 2018 guideline recommending that men aged 55 to 69 make individualized decisions about PSA screening through shared decision-making with their clinicians, did rural and urban men in the eligible age range end up receiving the test and participating in those discussions at comparable rates? The question matters because the 2018 guideline made the screening decision fundamentally conversational rather than automatic, and any barrier to meaningful patient–physician dialogue—such as shorter visits, physician shortages, or weaker primary care infrastructure in rural areas—could in theory translate into measurable disparities.

To investigate, the team turned to the National Health Interview Survey, a nationally representative household survey conducted by the National Center for Health Statistics at the Centers for Disease Control and Prevention. They pooled three cycles of the survey—2019, 2021, and 2023—focusing on men aged 55 and older. Men with a personal history of prostate cancer were excluded, since screening behavior is obviously different for those who have already been diagnosed, as were respondents with missing data on the key variables. The final analytic sample included 15,393 eligible respondents, a large enough pool to support statistically meaningful national estimates once the survey’s complex sampling design was accounted for. After applying the appropriate sampling weights, the researchers estimated that roughly 18 percent of American men in this age group resided in rural areas, a reminder that rural populations constitute a substantial share of the aging male population most affected by prostate cancer screening policy.

The researchers examined three distinct outcomes. The first was whether a man had ever received a PSA test in his lifetime, a measure of cumulative exposure to screening. The second was whether he had received a PSA test within the past 12 months, a closer proxy for current screening behavior in the post-2018 guideline era. The third, assessed only in the 2019 survey cycle, was participation in shared decision-making—that is, whether a clinician had engaged the patient in a discussion of the potential benefits and uncertainties of PSA testing before the test was ordered. This third measure is the most direct window into whether the 2018 guideline’s central mechanism, the informed conversation, is actually reaching patients outside major urban centers.

The headline numbers paint a picture of widespread but incomplete screening engagement. Sixty-one percent of men in the sample reported having received a PSA test at some point in their lives, 39 percent reported testing within the previous year, and among respondents to the 2019 cycle, 48 percent reported having participated in shared decision-making about the test. In other words, even in the post-guideline era, fewer than half of the men facing a screening decision described having had the kind of informed discussion that the US Preventive Services Task Force considers essential. That finding alone is noteworthy, and it holds across both rural and urban populations.

When the team fitted multivariable regression models that adjusted for the survey’s complex design and weighting, the expected rural–urban divide simply failed to materialize. For ever having received a PSA test, the adjusted odds ratio comparing rural and urban men was 0.96, with a 95 percent confidence interval of 0.85 to 1.09 and a p-value of 0.552—statistically indistinguishable from no difference. For testing within the past 12 months, the adjusted odds ratio was likewise 0.96 (95 percent confidence interval 0.85 to 1.07, p = 0.454). And for participation in shared decision-making, the adjusted odds ratio was 0.95 (95 percent confidence interval 0.78 to 1.15, p = 0.586). Across all three outcomes, the confidence intervals straddled the null value comfortably, indicating that whatever differences exist between rural and urban men in this dataset, they are small enough to be explained by random sampling variation.

The authors are careful about how these results should be interpreted, and their caution is instructive. One possibility is that the findings reflect a genuine convergence: following the 2018 guideline, screening conversations and PSA testing may have declined or leveled off similarly in both settings, erasing rural–urban gaps that might have existed earlier. Previous research had documented sharp drops in PSA testing after the Task Force’s controversial 2012 grade D recommendation against routine screening, and studies of the 2018 update found ongoing shifts in testing patterns, but few had examined those patterns specifically through a rural–urban lens at the national level. International evidence from New Zealand and Australia had suggested that remoteness of residence does influence PSA testing patterns, and American studies in regions such as Appalachia had documented more aggressive prostate cancer presentations in rural populations, making the absence of a disparity in screening behavior genuinely unexpected.

A second interpretation, which the authors highlight, involves the COVID-19 pandemic. Two of the three survey cycles included in the analysis—2021 and 2023—captured periods during and after unprecedented disruptions to routine medical care. National data from mid-2020 showed that large fractions of American adults delayed or avoided medical care because of pandemic-related concerns, and subsequent research documented declines in multiple preventive screenings, with some evidence that the disruptions disproportionately affected already disadvantaged groups. If preventive care utilization broadly collapsed during the pandemic years, the rural–urban contrast in PSA testing could have been compressed by a common denominator of reduced access, rather than by equitable improvement. The authors note that their findings might reflect declining preventive care utilization during the COVID-19 pandemic, or similarly low levels of testing and shared decision-making in both populations—two very different explanations with very different implications for policy.

The deeper concern raised by the study may therefore be less about geography than about the low absolute levels of shared decision-making itself. If only about half of eligible men report discussing PSA testing with a clinician before being tested, and that proportion is similar in cities and in the countryside, then the 2018 guideline’s ambition of individualized, informed screening choices is falling short everywhere. Prior studies have found that shared decision-making for PSA testing remains underutilized nationally and that its occurrence varies with patient, physician, and practice-level factors. Prostate cancer screening carries a well-documented tension: PSA testing has contributed to declines in prostate cancer mortality, yet it also generates false positives and detects slow-growing tumors that might never have caused harm, exposing men to biopsies and treatments with lasting side effects. Navigating that trade-off is precisely what shared decision-making is designed to accomplish, and its uneven uptake is a quality-of-care problem that transcends the rural–urban divide.

For clinicians and health systems, the study’s message is twofold. First, rural men in the post-2018 era do not appear to be systematically excluded from PSA screening or screening discussions relative to urban men, at least in self-reported national survey data—a finding that should temper assumptions of inevitable rural disadvantage in this specific domain. Second, and more soberingly, the quality of the screening decision itself appears suboptimal nationwide, with substantial room to improve whether patients live in Greenville, North Carolina, or Manhattan. Because the analysis relied on self-reported survey data, recall and reporting biases cannot be excluded, and the cross-sectional design cannot establish causality or track individual trajectories over time. Still, with a nationally representative sample spanning three survey cycles and rigorous adjustment for the sampling design, the study offers one of the clearest post-guideline snapshots to date of who is getting tested and who is being brought into the conversation. As health systems work to restore preventive care in the pandemic’s aftermath, the findings suggest that efforts to promote genuinely informed prostate cancer screening decisions should target all communities—not only those historically assumed to be left behind.

Subject of Research: Rural–urban disparities in prostate-specific antigen testing and shared decision-making among US men following the 2018 USPSTF prostate cancer screening guidelines

Article Title: Rural–urban disparities in prostate-specific antigen testing and shared decision-making in the US

Article References: Bates, N., Blute, M., Jr., Tumin, D., & Barnwell, P., Jr. (2026). Rural–urban disparities in prostate-specific antigen testing and shared decision-making in the US. Cancer Causes & Control, 37(9), Article 155. https://doi.org/10.1007/s10552-026-02243-z

Image Credits: AI Generated

DOI: 10.1007/s10552-026-02243-z

Keywords: prostate cancer, PSA testing, shared decision-making, rural health, health disparities, cancer screening, USPSTF guidelines, National Health Interview Survey, preventive care, COVID-19 pandemic, overdiagnosis, urology

China’s social health insurance framework is segmented into tiers based primarily on urban versus rural residency, occupation, and registration status, culminating in varying levels of benefits and reimbursement rates. This tiered structure essentially stratifies the insured population, introducing systemic inequities that disproportionately affect vulnerable groups, particularly those with severe or chronic conditions such as lung cancer. As lung cancer remains a leading cause of cancer-related mortality globally, and particularly in China where incidence rates have escalated sharply, understanding the intersection between insurance design and patient outcomes is critically important for informing policy reform.

The study conducted a comprehensive analysis using an extensive population-based dataset encompassing thousands of lung cancer patients hospitalized across multiple provinces. By deploying advanced statistical methodologies, including multivariate regression and propensity score matching, the researchers controlled for confounding variables and isolated the independent effects of insurance tier on both treatment decisions and inpatient costs. This methodical approach lends robustness to their findings, marking a significant step forward in quantifying healthcare inequities tied directly to insurance structures rather than individual patient health status or geographic disparities alone.

One of the most arresting revelations from the study is the extent to which patients enrolled in lower-tier social insurance—largely encompassing rural residents and informal sector workers—experience markedly less access to optimal inpatient treatments. These treatments often include state-of-the-art chemotherapy regimens, targeted therapies, and surgical interventions that are critical for improving survival rates in lung cancer. The research showed that patients with lower-tier coverage were not only less likely to receive these advanced treatments but also experienced delayed admission and shorter hospital stays, signaling a systemic barrier to comprehensive care.

Financial implications are equally profound. Inpatient expenditures for lung cancer patients under lower-tier insurance schemes were disproportionately burdensome relative to household income, frequently resulting in catastrophic out-of-pocket spending. The study’s economic analysis detailed how these patients faced a near doubling of co-payment rates and supplementary fees compared to their counterparts in higher-tier plans, translating into significant financial toxicity that often hinders adherence to treatment protocols and diminishes quality of life.

Moreover, the research elucidates the feedback loop between insurance inequities and clinical outcomes. Patients constrained by limited insurance benefits are less likely to complete full courses of treatment or receive palliative care options that can extend survival and improve symptom management. This dynamic exacerbates morbidity and mortality in already high-risk populations, calling into question the effectiveness of China’s current insurance stratifications in serving vulnerable cancer patients equitably.

The study also provides a granular, province-specific breakdown, highlighting regional disparities within China’s vast and heterogeneous healthcare ecosystem. Wealthier provinces with better-funded insurance pools tend to offer more generous benefits and lower patient cost-sharing, which corresponds with improved treatment access and outcomes. Conversely, economically disadvantaged provinces reinforced the “inverse care law,” where those most in need of care receive the least, underscoring a glaring need for policy harmonization nationwide.

From a technical perspective, the researchers meticulously adjusted for variables such as age, sex, cancer stage at diagnosis, comorbidity burdens, and hospital type to ensure that disparities observed were attributable to insurance tier effects rather than patient clinical characteristics. This rigorous approach provides clarity to policymakers striving to dismantle systemic barriers, signaling that reforms cannot focus solely on clinical improvements but must encompass financing mechanisms to reduce inequities.

The timing of this study is particularly critical given China’s ambitious health reform agenda aimed at universal health coverage and enhanced equity. Policymakers have been grappling with how best to integrate urban and rural insurance schemes to reduce fragmentation while maintaining sustainability. The findings by Zhang and colleagues provide compelling empirical evidence that tiered insurance designs, as currently implemented, perpetuate inequalities with deleterious patient and economic consequences. This elevates the discourse surrounding social health insurance reforms beyond theoretical frameworks to evidence-driven policy design.

Furthermore, this research contributes to global conversations about health equity. China’s tiered insurance model is not unique; many countries operate segmented insurance systems that stratify populations and create pockets of healthcare privilege and deprivation. The insights gained have transferable value for international health policy experts examining how disparate insurance financing can undermine broader goals of equity and universal access, particularly in managing chronic and high-cost diseases like cancer.

The study draws attention to the crucial role of inpatient care in lung cancer management. Although outpatient and community-based interventions continue to expand, inpatient hospitalization remains an indispensable component for delivering intensive treatments and managing complications. The documented disparities in inpatient utilization suggest systemic issues extending across the healthcare continuum, suggesting that reform efforts must encompass hospital funding, provider incentives, and patient copayment structures to be truly effective.

In addressing potential solutions, the authors discuss the ramifications of integrating benefit packages and reimbursement rates across insurance tiers. Such integration could mitigate out-of-pocket burdens and standardize treatment protocols, resulting in more equitable care delivery. However, the path to this is complex, requiring dialogue between government agencies, insurers, providers, and patient advocacy groups to balance fiscal sustainability with social justice imperatives.

Importantly, the study also highlights the necessity of data-driven monitoring frameworks. Continuous collection and analysis of patient-level data across insurance cohorts can help track progress, identify emerging disparities, and inform iterative policy adjustments. Transparency in outcomes and costs will empower stakeholders and enhance accountability in healthcare delivery systems.

This comprehensive study, with its meticulous methodology and clear implications, is poised to influence not only the design of social health insurance within China but also stimulate critical discussions worldwide about financing equity in oncology care. The intersection of economics, clinical medicine, and public policy explored here typifies the multidisciplinary approach needed to confront health disparities in the 21st century.

As lung cancer incidence continues to rise amid demographic shifts and environmental exposures, ensuring equitable, high-quality care across all socio-economic strata becomes a public health imperative. The findings presented urge reevaluation of entrenched insurance segmentation, calling for unified reforms that prioritize patient needs over bureaucratic classifications.

Ultimately, this research is a clarion call to action, inviting governments, healthcare providers, insurers, and researchers alike to confront the unresolved inequalities embedded in health insurance frameworks. By doing so, they can pave the way for a more just and effective healthcare system that delivers life-saving treatments to all lung cancer patients regardless of their insurance status or socio-economic background.

Subject of Research: Disparities in inpatient treatment and expenditures among lung cancer patients under tiered social health insurance in China.

Article Title: Disparities in inpatient treatment and expenditures among lung cancer patients under tiered social health insurance: a population-based study in China.

Article References:
Zhang, Y., He, Y., Wang, Q. et al. Disparities in inpatient treatment and expenditures among lung cancer patients under tiered social health insurance: a population-based study in China. Int J Equity Health 24, 163 (2025). https://doi.org/10.1186/s12939-025-02533-z

Image Credits: AI Generated